Gemin X Pan Bcl-2 Inhibitor Obatoclax Shows Biological, Clinical Activity In Heavily Pre-Treated Patients With Advanced Chronic Lymphocytic Leukemia

Gemin X, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced that one of its lead oncology candidates, obatoclax, has demonstrated biological and anti-cancer activity in heavily pre-treated patients with advanced chronic lymphocytic leukemia (CLL). The results are from a Phase 1 study, and have been published in the online version of Blood, the Journal of the American Society of Hematology.